This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-27 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The government announces that TikTok is to be banned on electronic devices used by ministers and other employees, amid security concerns relating to the Chinese-owned app's handling of user data. Scientists identify a gene variant that is known to increases the risk of breast and ovarian cancer, and trace it to people with Orkney Island heritage, more specifically those with ancestry on the island of Westray. COVID-19 in the UK: Office for National Statistics data for the week ending 7 March (6 March in Scotland) indicates COVID-19 cases are falling in Scotland, but the picture is uncertain in the rest of the UK. In England, the survey suggests that 1,322,000 tested positive for the virus, equating to 2.36% of the population, or around 1 in 40. 18 March – Peter Murrell resigns as CEO of the Scottish National Party amid a row over party membership. 19 March The UK government launches the Emergency Alerts service, a service to send text alerts to mobile phones in a situation where it is perceived there is an immediate risk to life. The BBC urges its staff to delete the TikTok app from its official devices amid concerns about its security. 20 March – The British government bans far-right Danish activist Rasmus Paludan from entering the United Kingdom over a threat to burn a Quran in Wakefield, West Yorkshire. 21 March Partygate scandal: Former prime minister Boris Johnson publishes a 52-page defence of his actions during the COVID-19 pandemic in which he acknowledges misleading Parliament over the Partygate scandal, but says he did not do so intentionally.
== References == Ladisch, Michael R. (2001). Bioseparations Engineering: Principles, Practice, and Economics. Wiley. ISBN 0-471-24476-7. Harrison, Roger G.; Paul W. Todd; Scott R. Rudge; Demetri Petrides (2003). Bioseparations science and engineering. Oxford University Press. ISBN 0-19-512340-9. Krishna Prasad, Nooralabettu (2010). Downstream Processing-A New Horizone in Biotechnology. Prentice Hall of India Pvt. Ltd, New Delhi. ISBN 978-81-203-4040-4.
Thanks to the protective function of radioprotectors, the dose of radiation used to treat malignant tumors (cancer) can be increased, thereby increasing the effectiveness of the therapy. There are also radiosensitizers, which increase the sensitivity of malignant tumor cells to ionizing radiation. As early as 1921, the German radiologist Hermann Holthusen (1886-1971) described that oxygen increases the sensitivity of cells.
Sources: en.wikipedia.org
A suture is a type of fibrous joint that is only found in the skull (cranial suture). The bones are bound together by Sharpey's fibres. A tiny amount of movement is permitted at sutures, which contributes to the compliance and elasticity of the skull. These joints are synarthroses. It is normal for many of the bones of the skull to remain unfused at birth. The fusion of the skull's bones before birth is known as craniosynostosis. The term "fontanelle" is used to describe the resulting "soft spots". The relative positions of the bones continue to change during the life of the adult (though less rapidly), which can provide useful information in forensics and archaeology. In old age, cranial sutures may ossify (turn to bone) completely. The joints between the teeth and jaws (gomphoses) and the joint between the mandible and the cranium, the temporomandibular joint, form the only non-sutured joints in the skull.
=== Polysaccharides === Polysaccharides (sugar polymers) can be linear or branched and are typically joined with glycosidic bonds. The exact placement of the linkage can vary, and the orientation of the linking functional groups is also important, resulting in α- and β-glycosidic bonds with numbering definitive of the linking carbons' location in the ring. In addition, many saccharide units can undergo various chemical modifications, such as amination, and can even form parts of other molecules, such as glycoproteins.
Vitamin or hormone supplements for what the body is lacking due to the disease (insulin, vitamin B12, thyroid hormone, etc.) Blood transfusions if the disease is blood related Physical therapy if the disease impacts bones, joints, or muscles Pharmaceutical treatment options include immunosuppressant drugs to reduce the immune response against the body's own tissues, such as:
Since radioactivity was discovered around the beginning of the 20th century, the main application of radioluminescence has been in radioluminescent paint, used on watch and compass dials, gunsights, aircraft flight instrument faces, and other instruments, allowing them to be seen in darkness. Radioluminescent paint consists of a mixture of a chemical containing a radioisotope with a radioluminescent chemical (phosphor). The continuous radioactive decay of the isotope's atoms releases radiation particles which strike the molecules of the phosphor, causing them to emit light. The constant bombardment by radioactive particles causes the chemical breakdown of many types of phosphor, so radioluminescent paints lose some of their luminosity during their working life. Radioluminescent materials may also be used in the construction of an optoelectric nuclear battery, a type of radioisotope generator in which nuclear energy is converted into light. The radioluminescence of nitrogen in air can be used to detect alpha radiation in nuclear contamination sites.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.